VIII. REFERENCES

1. Gordon LI et coll. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study. Blood. 2004 103:4429-31.
2. Zhu X. Radiation safety considerations with yttrium 90 ibritumomab tiuxetan (Zevalin). Semin Nucl Med. 2004 1:20-3.
3. Zimmer AM. Logistics of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin). Semin Nucl Med. 2004 1:14-9.
4. Borghaei H et coll. Safety and efficacy of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin). Semin Nucl Med. 2004 1:4-9.
5. Conti PS. Radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin): the role of the nuclear medicine physician. Semin Nucl Med. 2004 1:2-3.
6. Wiseman GA et coll. Phase I/II ⁹⁰Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. Eur J Nucl Med. 2000 Jul;27(7):766-77.
7. Wiseman GA et coll Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Crit Rev Oncol Hematol. 2001 Jul-Aug;39(1-2):181-94
8. Wiseman GA et coll. Radiation dosimetry results and safety correlations from ⁹⁰Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. J Nucl Med. 2003 Mar;44(3):465-74.